Replies to post #26807 on Marker Therapeutics Inc (MRKR)

[staccani]

Pembrolizumab was approved based on ph1 study results... so if PC results are compelling, an accelerated approval is not out of question..


https://www.ascopost.com/issues/october-15-2014/first-approval-of-pd-1-inhibitor-pembrolizumab-in-unresectable-or-metastatic-melanoma/